Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients who are not eligible for an autologous stem cell transplant, a Phase 3 clinical trial shows. Findings from the MAIA trial (NCT02252172) were published in The New England Journal of Medicine in the study, “Daratumumab…
